BMPR2 and pulmonary arterial hypertension: Ultimately, PAH remains incurable and median survival is merely 7 years [12], a prognosis that is worse in various PAH subtypes, including systemic sclerosis (SSc)-associated PAH and in bone morphogenetic protein receptor type II (BMPR2) mutation carriers [13].